Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

NCT05258279 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-squamous Non-small-cell Lung Cancer
EGFR Activating Mutation

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Juntendo University

Collaborators

[object Object]